What is XBIT's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.07B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for XBIT?

P/E (TTM) is n/a and 52-week range is $2.09 to $3.44 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s XBIT figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for XBIT?

The company profile lists revenue (TTM) near $4M, net income (TTM) near $-3.40B, EPS (TTM) near $-1.48 when available from the market-data feed. Figures are informational and may lag live markets.

Where is XBiotech Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Austin, Texas, US, 30.5M shares outstanding, ISIN CA98400H1029 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

XBiotech Inc

$XBIT

Health Care · Biotechnology

IR Run Scenarios

$2.29

+4.09%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

XBiotech, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutic antibodies. The company is headquartered in Austin, Texas and currently employs 85 full-time employees. The company went IPO on 2015-04-15. The firm's True Human monoclonal antibodies are derived from human donors that mount a natural human immune response. The firm is focused on therapies that block a potent substance, known as interleukin-1 alpha (IL-1a), that mediates a number of pathophysiological processes including tissue breakdown (i.e. synovium, cartilage, bone), paraneoplastic angiogenesis and tumor stroma remodeling, formation of blood clots, malaise, muscle wasting and general inflammation. The company has various candidate products, including Natrunix. The company has a clinical-stage therapeutic for methicillin resistant Staphylococcus aureus (MRSA), and several pre-clinical-stage therapeutics, including an oral delivery antibody therapeutic for colon infection by C. difficile.

Employees

Website

www.xbiotech.com/

IPO

2015-04-15

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)